SAT628 Effect Of Hepatic Impairment On The Pharmacokinetics, Safety, And Tolerability Of Oral Paltusotine, A Non-peptide, Selective Somatostatin Receptor Subtype 2 Agonist

Disclosure: R. Luo: Employee; Self; Crinetics Pharmaceuticals Inc. A. Casagrande: Employee; Self; Crinetics Pharmaceuticals Inc. S. Oun: Employee; Self; Crinetics Pharmaceuticals Inc. Y. Wang: Employee; Self; Crinetics Pharmaceuticals Inc. R. Struthers: Employee; Self; Crinetics Pharmaceuticals Inc....

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Rosa, Casagrande, Alessandra, Oun, Sonic, Wang, Yang, Scott Struthers, R, Krasner, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Neuroendocrinology & Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554205/
http://dx.doi.org/10.1210/jendso/bvad114.1361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554205/
http://dx.doi.org/10.1210/jendso/bvad114.1361

Ejemplares similares